Novartis announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will bolster its capacity and capabilities for early technical development of biologics. Spanning both drug substance and drug product development, the multi-year investment will be implemented across existing Novartis locations in Switzerland, Slovenia and Austria, strengthening Novartis ability to deliver on the increasing growth and diversity of its early-stage biotherapeutics portfolio.
- Read more about Novartis invest USD 300m to develop biotherapeutics portfolio
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/novartis-invest-usd-300m-to-develop-biotherapeutics-portfolio
No comments:
Post a Comment